WO1993014760A2 - Methods - Google Patents
Methods Download PDFInfo
- Publication number
- WO1993014760A2 WO1993014760A2 PCT/US1993/000730 US9300730W WO9314760A2 WO 1993014760 A2 WO1993014760 A2 WO 1993014760A2 US 9300730 W US9300730 W US 9300730W WO 9314760 A2 WO9314760 A2 WO 9314760A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- carbon atoms
- pharmaceutically acceptable
- solvate
- hydrate
- Prior art date
Links
- 0 CC1(**)CCCCC1 Chemical compound CC1(**)CCCCC1 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Definitions
- This invention relates to a method of preventing or delaying the occurrence of acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus (HIV) seropositive humans which comprises administering to such human an effective therefore amount of a substituted azaspirane.
- AIDS acquired immunodeficiency syndrome
- HIV human immunodeficiency virus
- immunosuppressive/immunomodulatory agents has been shown to suppress viral replication.
- CD8 lymphocytes have been shown to suppress replication of HIV in peripheral blood mononuclear cells (Waler et al. Science, 2-21:1563-6 (1986)) and activated CD8+ T cells have been shown to inhibit the replication of HIV in cultures of CD4+ cells from asymptomatic HIV seropositive individuals (Brinch ann et al. CD8+ T cells J. Immunol. 144 2961-2966 (1990)).
- the immunosuppressive compound cyclosporin A (CsA) has demonstrated a protective effect in several animal models of viral infection.
- Badger I discloses compounds of Formula I as a novel class of compounds which induce an immunomodulatory effect which is characterized by the stimulation of suppressor cell activity.
- R 1 and R 2 are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R 1 and R 2 when taken together is 5-10; or
- R 1 and R 2 together form a cyclic alkyl group having 3-7 carbon atoms
- R3 and R 4 are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R ⁇ and R 4 are joined together with the nitrogen atom to form a heterocyclic group having
- a preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I) where R 1 and R 2 are propyl, R3 and R 4 are methyl, is 1 and n is 3 which is N,N-dimethyl-8,8-dipropyl-2- azaspiro[4,5]decane-2-propanamine dihydrochloride.
- a preferred compound used in the novel method is a compound of Formula (I) where R 1 and R 2 are propyl, R ⁇ and R 4 are ethyl, m is 1 and n is 3 which is N,N- diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2- propanamine and salts thereof.
- This invention discloses compounds of Formula (I) and pharmaceutically acceptable salts or hydrates or solvates thereof as being useful for preventing or delaying the occurrence of AIDS in HIV seropositive humans.
- This invention relates to a method of delaying or preventing the occurrence of AIDS which comprises administering to an HIV seropositive human an effective therefor amount of a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof.
- a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof can be administered to such human in a conventional dosage form prepared by combining a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof, with a conventional pharmaceutically acceptable carrier or diluent according to known techniques, such as those described in Badger (I), U.S. Patent No. 4,963,557.
- a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof is administered to an HIV seropositive human in an amount sufficient to prevent or delay the occurrence of AIDS.
- the route of administration of the Formula (I) compound is not critical but is usually oral or parenteral, preferably oral.
- parenteral as used herein includes intravenous, intramuscular, subcutaneous, intranasal, intrarectal, transdermal, intravaginal or intraperitoneal administration.
- the subcutaneous and intramuscular forms of parenteral administration are generally preferred.
- the daily parenteral dosage regimen will preferably be from about 0.01 mg/kg to about 10 mg/kg of total body weight, most preferably from about 0.1 mg/kg to about 1 mg/kg.
- each parenteral dosage unit will contain the active ingredient in an amount of from about 0.1 mg to about 100 mg.
- the compounds of Formula (I) which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
- a liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent.
- a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent.
- a composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used or preparing solid formulations.
- suitable pharmaceutical carrier(s) include magnesium stearate, starch, lactose, sucrose and cellulose.
- a composition in the form of a capsule can be prepared using routine encapsulation procedures.
- pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s) , for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
- the daily oral dosage regimen will preferably be from about 0.01 mg/kg to about 10 mg/kg of total body weight.
- each oral dosage unit will contain the active ingredient in an amount of from about 0.1 mg to about 100 mg.
- an active ingredient While it is possible for an active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation.
- the optimal quantity and spacing of individual dosages of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof given per day and duration of therapy, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
- the compounds of the present invention can be co-administered with further active ingredients, such as other compounds known to prevent or delay the occurrence of AIDS in HIV seropositive humans such as retrovir (the brand name for zidovudine, formerly called azidothymidine (AZT) ) .
- retrovir the brand name for zidovudine, formerly called azidothymidine (AZT) .
- An oral dosage form for administering Formula (I) compounds is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Table I, below.
- EXAMPLE 2 - TN ECTABLE PARENTERAL COMPOSITION An injectable form for administering Formula (I) compounds is produced by stirring 1.5% by weight of N,N-dimeth l-8,8-dipropyl-2-azaspiro[4,5]decane-2- propanamine dihydrochloride in 10% by volume propylene glycol in water.
- sucrose, calcium sulfate dihydrate and Formula (I) compound shown in Table II below are mixed and granulated in the proportions shown with a 10% gelatin solution.
- the wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Invented is a method of preventing or delaying the occurrence of acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus (HIV) seropositive humans which comprises administering to such human an effective therefor amount of a substituted azaspirane.
Description
METHODS
This invention relates to a method of preventing or delaying the occurrence of acquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus (HIV) seropositive humans which comprises administering to such human an effective therefore amount of a substituted azaspirane.
Background of the Invention
The use of immunosuppressive/immunomodulatory agents has been shown to suppress viral replication.
Specifically, immunomodulating CD8 lymphocytes have been shown to suppress replication of HIV in peripheral blood mononuclear cells (Waler et al. Science, 2-21:1563-6 (1986)) and activated CD8+ T cells have been shown to inhibit the replication of HIV in cultures of CD4+ cells from asymptomatic HIV seropositive individuals (Brinch ann et al. CD8+ T cells J. Immunol. 144 2961-2966 (1990)). Further, the immunosuppressive compound cyclosporin A (CsA) has demonstrated a protective effect in several animal models of viral infection. Particularly, chronic treatment with CsA before and after infection with LP-B 5 murine leukemia virus has proven effective against the development of immunodeficiency disease (Cerny, A. et al. Eur. J. Immunol. 21:1747-50 (1991)). Evidence that treatment
of AIDS and HIV-seroposi ive non-AIDS patients with CsA increases T4 cells and inhibits lymphadenopathy has also been reported. (Andrieu et al. Clin. Immunol, and immnmopathol . 46:181-198 (1988)) .
Badger, et al., U.S. Patent No. 4,963,557 (Badger I) discloses compounds of the formula
wherein: n is 3-7; m is 1 or 2; R^ and R^ are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R^ and R^ when taken together is 5-10; or R?- and R2 together form a cyclic alkyl group having 3-7 carbon atoms; R^ and R^ are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R3 and R^ are joined together with the nitrogen atom to form a heterocyclic group having 5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof.
Badger I discloses compounds of Formula I as a novel class of compounds which induce an immunomodulatory effect which is characterized by the stimulation of suppressor cell activity.
Badger I does not disclose the compounds of Formula I as agents for preventing or delaying the occurrence of AIDS in HIV seropositive humans.
Summary of the Invention This invention relates to a method of preventing or delaying the occurrence of AIDS in HIV seropositive humans which comprises administering to such mammal an effective therefor amount of a compound of the formula
wherein: n is 3-7; m is 1 or 2;
R1 and R2 are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R1 and R2 when taken together is 5-10; or
R1 and R2 together form a cyclic alkyl group having 3-7 carbon atoms;
R3 and R4 are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R^ and R4 are joined together with the nitrogen atom to form a heterocyclic group having
5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof.
Detailed Description of the Invention
The preparation of all compounds of Formula (I) and pharmaceutically acceptable salts, hydrates and solvates and formulations thereof is disclosed in U.S. Patent No. 4,963,557, the entire disclosure of which is hereby incorporated by reference.
A preferred compound used in the novel method is the dihydrochloride salt of a compound of Formula (I)
where R1 and R2 are propyl, R3 and R4 are methyl, is 1 and n is 3 which is N,N-dimethyl-8,8-dipropyl-2- azaspiro[4,5]decane-2-propanamine dihydrochloride.
A preferred compound used in the novel method is a compound of Formula (I) where R1 and R2 are propyl, R^ and R4 are ethyl, m is 1 and n is 3 which is N,N- diethyl-8,8-dipropyl-2-azaspiro[4,5]decane-2- propanamine and salts thereof.
This invention discloses compounds of Formula (I) and pharmaceutically acceptable salts or hydrates or solvates thereof as being useful for preventing or delaying the occurrence of AIDS in HIV seropositive humans.
This invention relates to a method of delaying or preventing the occurrence of AIDS which comprises administering to an HIV seropositive human an effective therefor amount of a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof. A compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof can be administered to such human in a conventional dosage form prepared by combining a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof, with a conventional pharmaceutically acceptable carrier or diluent according to known techniques, such as those described in Badger (I), U.S. Patent No. 4,963,557.
It will be recognized by one of skill in the art that the form and character of the pharmaceutically acceptable carrier or diluent is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well- known variables. A compound of Formula (I) or a
pharmaceutically acceptable salt or hydrate or solvate thereof is administered to an HIV seropositive human in an amount sufficient to prevent or delay the occurrence of AIDS.
The route of administration of the Formula (I) compound is not critical but is usually oral or parenteral, preferably oral.
The term parenteral as used herein includes intravenous, intramuscular, subcutaneous, intranasal, intrarectal, transdermal, intravaginal or intraperitoneal administration. The subcutaneous and intramuscular forms of parenteral administration are generally preferred. The daily parenteral dosage regimen will preferably be from about 0.01 mg/kg to about 10 mg/kg of total body weight, most preferably from about 0.1 mg/kg to about 1 mg/kg. Preferably, each parenteral dosage unit will contain the active ingredient in an amount of from about 0.1 mg to about 100 mg.
The compounds of Formula (I) which are active when given orally can be formulated as liquids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or pharmaceutically acceptable salt in a suitable liquid carrier(s) for example, ethanol, glycerine, non-aqueous solvent, for example polyethylene glycol, oils, or water with a suspending agent, preservative, flavoring or coloring agent.
A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s)
routinely used or preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s) , for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
The daily oral dosage regimen will preferably be from about 0.01 mg/kg to about 10 mg/kg of total body weight. Preferably each oral dosage unit will contain the active ingredient in an amount of from about 0.1 mg to about 100 mg.
While it is possible for an active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation.
It will be recognized by one of skill in the art that the optimal quantity and spacing of individual dosages of a compound of formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of a compound of Formula (I) or a pharmaceutically acceptable salt or hydrate or solvate thereof given per day and duration
of therapy, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
In addition, the compounds of the present invention can be co-administered with further active ingredients, such as other compounds known to prevent or delay the occurrence of AIDS in HIV seropositive humans such as retrovir (the brand name for zidovudine, formerly called azidothymidine (AZT) ) .
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following examples are, therefore, to be construed as merely illustrative and not a limitation of the scope of the present invention in any way.
EXAMPLE 1 - CAPSULE COMPOSITION
An oral dosage form for administering Formula (I) compounds is produced by filing a standard two piece hard gelatin capsule with the ingredients in the proportions shown in Table I, below.
Table I
INGREDIENTS AMOUNTS
N,N-dimethyl-8,8-dipropyl-2- 25 mg azaspiro[4,5]decane-2-propanamine dihydrochloride
Lactose 55 mg
Talc 16 mg
Magnesium Stearate 4 mg
EXAMPLE 2 - TN ECTABLE PARENTERAL COMPOSITION
An injectable form for administering Formula (I) compounds is produced by stirring 1.5% by weight of N,N-dimeth l-8,8-dipropyl-2-azaspiro[4,5]decane-2- propanamine dihydrochloride in 10% by volume propylene glycol in water.
Example 3 - Tablet Compos on
The sucrose, calcium sulfate dihydrate and Formula (I) compound shown in Table II below, are mixed and granulated in the proportions shown with a 10% gelatin solution. The wet granules are screened, dried, mixed with the starch, talc and stearic acid, screened and compressed into a tablet.
While the above descriptions and examples fully describe the invention and the preferred embodiments thereof, it is understood that the invention is not limited to the particular disclosed embodiments coming within the scope of the following claims.
Claims
1. A method for preventing or delaying the occurrence of acquired immunodeficiency syndrome (AIDS) in human immumodeficiency virus (HIV) seropositive humans which comprises administering to such human an effective therefor amount of a compound of the formula
wherein: n is 3-7; m is 1 or 2; R1 and R2 are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R1 and R2 when taken together is 5-10; or R1 and R2 together form a cyclic alkyl group having 3- 7 carbon atoms;
R3 and R4 are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R3 and R4 are joined together with the nitrogen to form a heterocyclic group having 5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof.
2. The method of claim 1 wherein the compound is N,N-diethyl-8, 8-dipropyl-2-azaspiro [4, 5] decane-2- propanamine; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
3. The method of claim 1 wherein the compound is administered orally.
4. The method of claim 3 wherein from about 0.01 mg/kg to about 10 mg/kg of compound is administered per day.
5. The method of claim 1 wherein the compound is administered parenterally.
6. The method of claim 5 wherein from about 0.01 mg/kg to about 10 mg/kg of compound is administered per day.
7. Use of a compound of the formula:
wherein: n is 3-7; m is 1 or 2;
R1 and R2 are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R1 and R2 when taken together is 5-10; or R1 and R2 together form a cyclic alkyl group having 3- 7 carbon atoms;
R3 and R4 are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R3 and R4 are joined together with the nitrogen to form a heterocyclic group having 5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof; in the manufacture of a medicament for preventing or delaying the occurrence of aquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus (HIV) seropositive humans.
8. The use according to claim 7 wherein the compound is N,N-diethyl-8,8-dipropyl-2- azaspiro[4,5]decane-2-propanamine; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
9. The use according to claim 7 wherein the compound is administered orally.
10. The use according to claim 9 wherein from about 0.01 mg/kg to about 10 mg/kg of compound is administered per day.
11. The use according to claim 7 wherein the compound is administered parenterally.
12. The use according to claim 11 wherein from about 0.01 mg/kg to about 10 mg/kg of compound is administered per day.
13. A pharmaceutical composition for use in preventing or delaying the occurrence of aquired immunodeficiency syndrome (AIDS) in human immunodeficiency virus (HIV) seropositive humans, comprising a compound of the formula:
R1 and R2 are the same or different and are selected from hydrogen or straight or branched chain alkyl, provided that the total number of carbon atoms contained by R1 and R2 when taken together is 5-10; or R! and R2 together form a cyclic alkyl group having 3- 7 carbon atoms;
R3 and R4 are the same or different and are selected from hydrogen or straight chain alkyl having 1-3 carbon atoms; or R3 and R4 are joined together with the nitrogen to form a heterocyclic group having 5-8 atoms; or a pharmaceutically acceptable salt or hydrate or solvate thereof.
14. A composition according to claim 13 wherein the compound is N, N-diethyl-8 ,8-dipropyl-2- azaspiro[4,5]decane-2-propanamine; or a pharmaceutically acceptable salt, hydrate or solvate thereof.
15. A composition according to claim 13 wherein the compound is administered orally.
16. A composition according to claim 15 wherein from about 0.01 mg/kg to about 10 mg/kg of compound is administered per day.
17. A composition according to claim 13 wherein the compound is administered parenterally.
18. A composition according to claim 17 wherein from about 0.01 mg/kg to about 10 mg/kg of compound is administered per day.
Priority Applications (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1019940702596A KR950700068A (en) | 1992-01-28 | 1993-01-27 | A method for delaying HIV in-duced AIDS by administration of substituted azasperane compounds by administering a substituted azaspiran compound |
| AU35951/93A AU666175B2 (en) | 1992-01-28 | 1993-01-27 | A method for delaying HIV induced AIDS by administration of substituted azasperane compounds |
| EP93904671A EP0624089A4 (en) | 1992-01-28 | 1993-01-27 | Methods. |
| US08/256,708 US5482959A (en) | 1992-01-28 | 1993-01-27 | Method for delaying aids in an HIV infected individual by administration of substituted azaspirane compounds |
| JP5513407A JPH07503252A (en) | 1992-01-28 | 1993-01-27 | Method for delaying HIV-induced AIDS by administration of substituted azasperane compounds |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9201803.5 | 1992-01-28 | ||
| GB929201803A GB9201803D0 (en) | 1992-01-28 | 1992-01-28 | Methods |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1993014760A2 true WO1993014760A2 (en) | 1993-08-05 |
| WO1993014760A3 WO1993014760A3 (en) | 1993-09-02 |
Family
ID=10709398
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1993/000730 WO1993014760A2 (en) | 1992-01-28 | 1993-01-27 | Methods |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP0624089A4 (en) |
| JP (1) | JPH07503252A (en) |
| KR (1) | KR950700068A (en) |
| AU (1) | AU666175B2 (en) |
| CA (1) | CA2128535A1 (en) |
| GB (1) | GB9201803D0 (en) |
| WO (1) | WO1993014760A2 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0711160A1 (en) * | 1993-07-23 | 1996-05-15 | Smithkline Beecham Corporation | Method of inhibiting the replication of human immunodeficiency viruses with substituted azaspiranes |
| EP0713391A1 (en) * | 1993-07-23 | 1996-05-29 | Smithkline Beecham Corporation | Method of inhibiting the production of human immunodeficiency viruses with substituted azaspiranes |
| EP0717622A1 (en) * | 1993-07-23 | 1996-06-26 | Smithkline Beecham Corporation | Methods of treating hiv with azaspiranes |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7273859B2 (en) * | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US181704A (en) * | 1876-08-29 | Improvement in flour-dressing machines | ||
| US4963557A (en) * | 1987-09-28 | 1990-10-16 | Smithkline Beecham Corporation | Immunomodulatory azaspiranes |
| EP0550595A4 (en) * | 1990-09-24 | 1993-09-08 | Smithkline Beecham Corporation | Methods |
| ZA921120B (en) * | 1991-02-19 | 1993-01-27 | Smithkline Beecham Corp | Cytokine inhibitors |
-
1992
- 1992-01-28 GB GB929201803A patent/GB9201803D0/en active Pending
-
1993
- 1993-01-27 WO PCT/US1993/000730 patent/WO1993014760A2/en not_active Application Discontinuation
- 1993-01-27 CA CA002128535A patent/CA2128535A1/en not_active Abandoned
- 1993-01-27 KR KR1019940702596A patent/KR950700068A/en not_active Ceased
- 1993-01-27 EP EP93904671A patent/EP0624089A4/en not_active Withdrawn
- 1993-01-27 JP JP5513407A patent/JPH07503252A/en active Pending
- 1993-01-27 AU AU35951/93A patent/AU666175B2/en not_active Ceased
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0711160A1 (en) * | 1993-07-23 | 1996-05-15 | Smithkline Beecham Corporation | Method of inhibiting the replication of human immunodeficiency viruses with substituted azaspiranes |
| EP0713391A1 (en) * | 1993-07-23 | 1996-05-29 | Smithkline Beecham Corporation | Method of inhibiting the production of human immunodeficiency viruses with substituted azaspiranes |
| EP0717622A1 (en) * | 1993-07-23 | 1996-06-26 | Smithkline Beecham Corporation | Methods of treating hiv with azaspiranes |
| EP0713391A4 (en) * | 1993-07-23 | 1998-09-09 | Smithkline Beecham Corp | Method of inhibiting the production of human immunodeficiency viruses with substituted azaspiranes |
| EP0711160A4 (en) * | 1993-07-23 | 1998-09-09 | Smithkline Beecham Corp | Method of inhibiting the replication of human immunodeficiency viruses with substituted azaspiranes |
| EP0717622A4 (en) * | 1993-07-23 | 1998-09-09 | Smithkline Beecham Corp | Methods of treating hiv with azaspiranes |
Also Published As
| Publication number | Publication date |
|---|---|
| AU666175B2 (en) | 1996-02-01 |
| CA2128535A1 (en) | 1993-08-05 |
| AU3595193A (en) | 1993-09-01 |
| WO1993014760A3 (en) | 1993-09-02 |
| JPH07503252A (en) | 1995-04-06 |
| EP0624089A4 (en) | 1994-12-14 |
| EP0624089A1 (en) | 1994-11-17 |
| GB9201803D0 (en) | 1992-03-11 |
| KR950700068A (en) | 1995-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2904827B2 (en) | Use of trifluoromethylphenyltetrahydropyridine in the preparation of a pharmaceutical composition useful for treating anxiety and anxiety-depressive disorders | |
| AU601237B2 (en) | The use of paroxetine to treat pain | |
| JPH0134970B2 (en) | ||
| UA81003C2 (en) | Use of a combination containing a non-nucleoside reverse transcriptase inhibitor (nnrti) with an inhibitor of cytochrome p450 | |
| US5482959A (en) | Method for delaying aids in an HIV infected individual by administration of substituted azaspirane compounds | |
| WO1993014760A2 (en) | Methods | |
| EP0713391A1 (en) | Method of inhibiting the production of human immunodeficiency viruses with substituted azaspiranes | |
| CA2066834A1 (en) | Use of glycine/nmda receptor ligands for the treatment of drug dependence and withdrawal | |
| WO1995003042A1 (en) | Method of inhibiting the replication of human immunodeficiency viruses with substituted azaspiranes | |
| WO1995003049A1 (en) | Methods of treating hiv with azaspiranes | |
| AU710542B2 (en) | Use of substituted azaspirane in the treatment of asthma | |
| AU684384B2 (en) | Method of treating opportunistic infections with azaspiranes | |
| US5786376A (en) | Methods of treating opportunistic infections with azaspiranes | |
| JPH09500647A (en) | A method for inhibiting human immunodeficiency virus production by substituted azaspirans. | |
| WO1993015735A1 (en) | (non descriptive)-a method for delaying hiv individual aids by administration of substituted azaspirane compounds | |
| MXPA98009596A (en) | Use of azaspiran substituted in the treatment of a | |
| WO1995003048A1 (en) | Anti-hiv azaspiranes | |
| WO1995003046A1 (en) | A method of inhibiting the production of hiv | |
| JPS6231682B2 (en) | ||
| WO1995003047A1 (en) | Human immunodeficiency virus treatments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| CFP | Corrected version of a pamphlet front page |
Free format text: REVISED TITLE RECEIVED BY THE INTERNATIONAL BUREAU AFTER COMPLETION OF THE TECHNICAL PREPARATIONS FOR INTERNATIONAL PUBLICATION |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2128535 Country of ref document: CA |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 08256708 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1993904671 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1993904671 Country of ref document: EP |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1993904671 Country of ref document: EP |